HAVN Life is Looking for a Safe Haven to Mental Health Through Psychedelic Medicine
Most companies' success stories come as a result of wanting to accomplish a greater purpose. For HAVN Life Sciences Inc. (CSE: HAVN) (OTC PINK: HAVLF) (FSE: 5NP) CEO Tim Moore, his personal experience took him to explore alternatives beyond traditional pharma.
Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound.